Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Double E who wrote (2859)	7/25/1999 10:21:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4140

Below are some of the "non-biased" ODP members who voted 4-3 to approve VISX for Astigmatism. Recognize any names here??? For Your Information: Marc Odrich, MD, practices at Columbia Presbyterian Eastside, 16 E. 60th Street, New York, NY; (888) CVC-1660. Dr. Odrich did not disclose whether or not he has a direct financial interest in the products mentioned in this article. He is a paid consultant for Visx. A. Ralph Rosenthal, MD, and Malvina Eydelman, MD, can be reached at the Food and Drug Administration, Division of Ophthalmic Devices, 9200 Corporate Boulevard, Rockville, MD 20850; (301) 594-2205; fax: (301) 480-4201. Drs. Rosenthal and Eydelman did not disclose whether or not they have a direct financial interest in the products mentioned in this article or if they are paid consultants for any companies mentioned. James Salz, MD, practices at Suite 390W, Cedars Sinai Medical, 8635 W. Third St., Los Angeles, CA 90048; (310) 652-1133; fax: (310) 657-1719; e-mail: jjsalzeye@aol.com. Dr. Salz has a direct financial interest in and is a paid consultant for Visx. James P. McCulley, MD, practices at The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9057; (214) 648-3407; fax: (214) 648-2382. Dr. McCulley has no direct financial interest in the products mentioned in this article, nor is he a paid consultant for any companies mentioned. Marc Bullimore, MCOptom, PhD, teaches at Ohio State University, 338 W. 10th Ave., Columbus, OH 43210, phone (614) 292-4724, fax (614) 292-4949; e-mail: bullimore.1@osu.edu. Dr. Bullimore has no direct financial interest in the products mentioned in this article, nor is he a paid consultant for any companies mentioned. Woodford Van Meter, MD, practices at Central Medical Plaza, 1760 Nicholasville Rd., Suite 203, Lexington, KY 90503; (606) 275-4001; fax: (606) 275-1142. Dr. Van Meter has no direct financial interest in the products mentioned in this article, nor is he a paid consultant for any companies mentioned. slackinc.com

To: Double E who wrote (2859)	7/26/1999 11:43:00 AM
From: BARRY ALLEN	Read Replies (2) \| Respond to of 4140

Hopefully all the selling is over. On Friday, trading 27 million shares, everyone who wanted out, got out. Today, all the margin calls hit and forced more people to sell. So far 9 million shares traded. SNRS has almost turned the float, which at this point is good. Now, let the buying begin and let the price get back to where this company is really worth. IMHO, $5-6 short term (this week) and $8-9 intermediate term (30 days). SNRS is way oversold at this point. LTK works and will eventually be approved. Sometimes new technology is kept from rapidly being brought to the marketplace because of poor education of the people making these decisions. Unfortunately, the company and shareholders did not foresee this. Below is a buy rec. put out on SNRS this morning! Sunrise Technologies - Sunrise got creamed on Friday after an FDA advisory committee voted to not approve the company's laser thermal keratoplasty system used for treating farsightedness. However, the product is currently used across the world, and the CEO feels confident that with more data, Sunrise will eventually convince the FDA to approve the treatment for the United States. dartz.com